Fig. 3: Probability of progression at 2 years in the four different subgroups of patients according to the model 2/20/20 plus cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q/monosomy 13). | Blood Cancer Journal

Fig. 3: Probability of progression at 2 years in the four different subgroups of patients according to the model 2/20/20 plus cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q/monosomy 13).

From: International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Fig. 3

This model defined four groups of SMM patients: low risk with none of the factors had a progression risk at 2 years of 6%, low–intermediate with one factor present had a progression risk at 2 years of 23%, intermediate risk with the presence of 2 factors had a risk of progression at 2 years of 37%, and the high risk with ≥3 of the factors had a progression risk at 2 years of 63%.

Back to article page